Market

VC money booms in Q2, with mega-deals hitting record levels

If it wasn’t clear from the firehose of financing deals we’ve covered over the past few months, it’s now official: VC activity is booming in healthcare, with Q2 drawing in $5.1 billion in capital.

That’s 22% of the total $23 billion raised by all VC-backed companies in the US, according to a new quarterly report from Pricewaterhouse Coopers.

Tom Ciccolella,

And as we noted in our China VC special report earlier this week, mega-deals over $100 million are on the rise in a big way. PwC said we’ve officially hit record-breaking numbers, with VC-backed US companies raising 45 mega-rounds in Q2. That’s up from 35 last quarter.

“2018’s mega-rounds are currently on pace to beat what was an unprecedented 2017 — which posted 111 mega-rounds,” said Tom Ciccolella, partner at PwC, in the report.

We happen to know biotech plays a big role here. In the first half of the year, we counted at least 12 mega-rounds totaling more than $100 million. In fact, two of the seven massive deals PwC highlighted as the biggest in its report were biotech ventures: Grail’s $300 million round, and Allogene’s $300 million deal.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Director/Sr Director, Oncology/Immuno-Oncology
Aro Biotherapeutics Company Denver, CO
Director/Sr. Director Oncology
Aro BioTx Philadelphia, PA
Manufacturing Associate – Upstream
Molecular Templates Austin, TX
Scientist, Process Development
Molecular Templates Austin, TX

Visit Endpoints Careers ->